Correlation Between Affimed NV and Atreca
Can any of the company-specific risk be diversified away by investing in both Affimed NV and Atreca at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Affimed NV and Atreca into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Affimed NV and Atreca Inc, you can compare the effects of market volatilities on Affimed NV and Atreca and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Affimed NV with a short position of Atreca. Check out your portfolio center. Please also check ongoing floating volatility patterns of Affimed NV and Atreca.
Diversification Opportunities for Affimed NV and Atreca
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Affimed and Atreca is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Affimed NV and Atreca Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Atreca Inc and Affimed NV is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Affimed NV are associated (or correlated) with Atreca. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Atreca Inc has no effect on the direction of Affimed NV i.e., Affimed NV and Atreca go up and down completely randomly.
Pair Corralation between Affimed NV and Atreca
If you would invest (100.00) in Atreca Inc on December 29, 2024 and sell it today you would earn a total of 100.00 from holding Atreca Inc or generate -100.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
Affimed NV vs. Atreca Inc
Performance |
Timeline |
Affimed NV |
Atreca Inc |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Affimed NV and Atreca Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Affimed NV and Atreca
The main advantage of trading using opposite Affimed NV and Atreca positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Affimed NV position performs unexpectedly, Atreca can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atreca will offset losses from the drop in Atreca's long position.Affimed NV vs. ADC Therapeutics SA | Affimed NV vs. Agenus Inc | Affimed NV vs. X4 Pharmaceuticals | Affimed NV vs. Terns Pharmaceuticals |
Atreca vs. Passage Bio | Atreca vs. Stoke Therapeutics | Atreca vs. Revolution Medicines | Atreca vs. Black Diamond Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Fundamental Analysis View fundamental data based on most recent published financial statements |